{"entity":{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","aka":[],"tldr":"A phase 3 trial of Tafasitamab, Rituximab, Lenalidomide in follicular lymphoma, run by Incyte Corporation, active and no longer recruiting.","summary":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. is a phase 3 interventional study registered as NCT04680052 by Incyte Corporation, with 654 participants enrolled, started 2021-04-15 and due to reach its primary completion in 2024-02-23. Interventions recorded: tafasitamab, rituximab, lenalidomide, placebo. Conditions listed: Follicular Lymphoma, Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04680052","url":"https://clinicaltrials.gov/study/NCT04680052"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tafasitamab","rituximab","lenalidomide"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04680052","phase":"3","setting":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma","sponsor":"Incyte Corporation","enrolled":654,"outcomes":[]},"route":"/trials/nct04680052/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}]}}